ArticleBMC microbiology2026
Probiotic potential of Lactobacillus helveticus CMI1 isolated from Iranian Khiki cheese: antimicrobial, anti-biofilm, and antioxidant properties for food preservatives.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveLactic acid bacteria (LAB) are widely recognized for their probiotic and antimicrobial potential in food and health-related applications. This study aimed to isolate and characterize Lactobacillus helveticus strain CMI1 from traditional Iranian Khiki cheese and to evaluate its probiotic-related properties, including antimicrobial, anti-biofilm, antioxidant, and cytotoxic activities.
methodsThe isolate was identified by 16S rRNA gene sequencing. Antimicrobial activity of acidic and neutralized cell-free supernatants (CFS) was evaluated against major Gram-positive and Gram-negative foodborne pathogens using disk diffusion, well diffusion, modified double-layer, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) assays. Anti-biofilm activity against Staphylococcus aureus was assessed using crystal violet staining and quantitative real-time PCR analysis of biofilm-related genes. Antioxidant activity was determined using DPPH, ABTS, and β-carotene/linoleic acid assays. Cytotoxic effects were evaluated against HT-29, HeLa, and MCF-7 cancer cell lines using the MTT assay. Antibiotic susceptibility was also examined.
resultsL. helveticus CMI1 exhibited strong antimicrobial activity, with higher efficacy observed for acidic CFS compared to neutralized CFS, particularly against S. aureus. The strain significantly inhibited S. aureus biofilm formation and downregulated key biofilm- and virulence-related genes (mecA, agr, spa, icaA, and hla). Additionally, CMI1 demonstrated notable antioxidant activity and dose-dependent cytotoxic effects against cancer cell lines, while remaining sensitive to clinically relevant antibiotics.
conclusionThese findings indicate that L. helveticus CMI1 possesses promising probiotic and functional properties, supporting its potential application in food preservation and functional food development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.